Inactive Instrument

IMARA

Equities

IMRA

US45249V1070

IMARA Inc. Announces Separate of Kenneth Attie as Chief Medical Officer, Effective April 20, 2022

April 15, 2022 at 02:31 am IST

On April 12, 2022, the board of directors of IMARA Inc. approved a reduction of the company's workforce (the workforce reduction) by approximately 83% across all areas of the company, to a total of six remaining full-time employees. In connection with the Workforce Reduction, Kenneth Attie, M.D., the company's chief medical officer will separate from the company effective April 20, 2022.

Latest news about IMARA

Enliven Therapeutics Completes Merger With Imara	24/23/24	MT
IMARA Inc.(NasdaqGS:IMRA) dropped from NASDAQ Composite Index	23/23/23	CI
Enliven Therapeutics, Inc. completed the acquisition of IMARA Inc. from a group of shareholders for approximately $340 million in a reverse merger transaction.	23/23/23	CI
IMARA Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	11/23/11	CI
Top Premarket Decliners	09/23/09	MT
Cardurion Pharmaceuticals, LLC acquired Tovinontrine (IMR-687) and All of the Assets Related to PDE9 Program from IMARA Inc. for approximately $95.	10/22/10	CI
IMARA Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	26/22/26	CI
Sector Update: Health Care Stocks Ending with Modest Declines	15/22/15	MT
Sector Update: Health Care Stocks Sliding with Broader Friday Markets	15/22/15	MT
Top Midday Gainers	14/22/14	MT
Wall Street Set to Open Higher as Earnings Season Accelerates, Ahead of Consumer Sentiment Survey	14/22/14	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	14/22/14	MT
Sector Update: Health Care	14/22/14	MT
US Stock Futures Mixed as Earnings Season Accelerates, Ahead of Consumer Sentiment Survey	14/22/14	MT
Top Premarket Gainers	14/22/14	MT
Arix Bioscience Portfolio Company Imara To Merge With Enliven Therapeutics	14/22/14	MT
IMARA, Enliven Therapeutics to Merge in All-Stock Deal; Shares Rise After Hours	14/22/14	MT
Transcript : Enliven Therapeutics, Inc., IMARA Inc. - M&A Call	14/22/14
Enliven Therapeutics, Inc. entered into a definitive merger agreement to acquire IMARA Inc. from a group of shareholders in a reverse merger transaction.	13/22/13	CI
Sector Update: Health Care Stocks Gaining Steam in Late Trade	08/22/08	MT
Sector Update: Health Care Stocks Rebounding Wednesday After Long Retreat	07/22/07	MT
Top Midday Gainers	07/22/07	MT
Sector Update: Health Care	07/22/07	MT
Imara to Sell Tovinontrine, PDE9 Program-Related Assets to Cardurion Pharmaceuticals; Shares Rise	07/22/07	MT
Top Premarket Gainers	07/22/07	MT

Chart IMARA

Duration

Period

More charts

Company Profile

Imara, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9). PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule. IMR-687 is in Phase IIb clinical development for the treatment of sickle cell disease (SCD) and beta- thalassemia. It is also focused on initiating a Phase II clinical trial of IMR-687 in heart failure with preserved ejection fraction (HFpEF). The Company is also focused on development of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2-related factor 2 (Nrf2).

Sector

More about the company